Mov Disord Vol 35, Suppl 1 Archives - Page 72 of 149 - MDS Abstracts

MDS Virtual Congress 2020
Comparison of gait measures in a clinic and a community setting in people with and without Parkinson’s disease
V. Shah, J. McNames, M. Mancini, P. Carlson-Kuhta, J. Nutt, M. El Gohary, C. Curtze, F. Horak (Portland, OR, USA)
Objective: This study aimed to investigate measures that best discriminated gait characteristics of people with Parkinson's disease (PD) from age-matched healthy control subjects (HC) in…
MDS Virtual Congress 2020
On-Demand Treatment Preferences of Patients with Parkinson’s Disease and “OFF” Episodes: Heterogeneity Across Patient Subgroups
A. Thach, J. Coulter, C. Leach, J. Sutphin, C. Mansfield (Marlborough, MA, USA)
Objective: To quantify preference heterogeneity for on-demand treatments among patients with Parkinson’s disease (PD) and “OFF” episodes. Background: Patients with PD commonly experience “OFF” episodes.…
MDS Virtual Congress 2020
Opicapone in fluctuating Parkinson’s disease: The daily clinical practice
L. Armengou Garcia, G. Martí-Andrés, R. Valentí Azcárate, I. Esparragosa Vázquez, C. Toledano Illán, R. Villino Boquete, R. Luquin (Pamplona, Spain)
Objective: To evaluate the effectiveness, tolerability and safety of opicapone as add-on to levodopa (LD) in the daily clinical practice in fluctuating Parkinson’s disease (PD)…
MDS Virtual Congress 2020
Evidence towards the clinical benefits of using directional leads in Deep Brain Stimulation for movement disorders: Consecutive case series
M. Contreras, J. Saavedra, J. Espinoza, G. Arango, T. Lopez (La Serena, Chile)
Objective: The objective of the present study was determinate the clinical benefits using directional leads in DBS in two different centers. Background: Deep brain stimulation…
MDS Virtual Congress 2020
Efficacy and tolerability of opicapone in Parkinson´s disease in usual clinical practice
V. Gomez-Mayordomo, F. Alonso-Frech, E. Lopez-Valdes, R. Garcia-Ramos, M. Catalan-Alonso (Madrid, Spain)
Objective: To evaluate the efficacy and tolerability of opicapone in usual clinical practice in patients with Parkinson's disease (PD). Background: Opicapone is a recently approved…
MDS Virtual Congress 2020
The Effect of Rasagiline on Motor and Non-Motor Symptoms in Parkinson’s Disease
B.G Koçer, E.A Özturk, SS. Çomoğlu (Ankara, Turkey)
Objective: In this study, we aimed to evaluate the effect of rasagiline treatment on motor and non-motor symptoms in patients with Parkinson’s disease (PD). Background:…
MDS Virtual Congress 2020
All-cause mortality in pimavanserin and atypical antipsychotic users with Parkinson’s disease in Medicare
A. Mosholder, Y. Ma, S. Akhtar, G. Podskalny, Y. Wei, J. Liao, Y. Feng, H. Lyu, M. Wernecke, K. Leishear, L. Nelson, T. MaCurdy, J. Kelman, D. Graham (Silver Spring, MD, USA)
Objective: To assess all-cause mortality in Medicare beneficiaries with Parkinson’s disease (PD) receiving pimavanserin or atypical antipsychotics (AAs). Background: In PD patients, the lifetime prevalence…
MDS Virtual Congress 2020
A pilot study on the shift from rasagiline to safinamide in fluctuating Parkinson’s disease patients
M.S Sforza, F.E Pontieri, D.R Rinaldi, E.B Bianchini (Rome, Italy)
Objective: Here we investigated the consequences of the shift from rasagiline (RS) to SF in fluctuating PD patients. To this end, we selected patients from…
MDS Virtual Congress 2020
A monocentric experience of Apomorphine pump follow-up on PD patients: The Optipump Cohort
C. Virbel-Fleischman, M. Houot, Y. Rétory, S. Hardy, J.C Corvol, D. Grabli (Gentilly, France)
Objective: The goal of this study is to describe the factors that may have an impact on Continuous Subcutaneous Apomorphine Infusion (CSAI) therapy initiation and…
MDS Virtual Congress 2020
Towards a scoring system to distinguish early parkinsonian variant of multiple system atrophy from Parkinson’s disease
P. Millar Vernetti, J.A Palma, L. Norcliffe-Kaufmann, M. Pérez, A. Fanciulli, F. Krismer, W. Singer, P. Low, M.T Pellecchia, H.J Kim, C. Shibao, A. Peltier, I. Biaggioni, M.J Martí, C. Terroba-Chambi, M. Merello, D. Goldstein, R. Freeman, C. Gibbons, S. Vernino, G. Wenning, H. Kaufmann (New York, NY, USA)
Objective: To develop a clinical score to distinguish between the parkinsonian variant of multiple system atrophy (MSA-P) and Parkinson’s disease (PD). Background: The differential diagnosis…